

Parenteral Technology Supplement 2026



Brought to you by **PMPS** and **SHL MEDICAL**
Pharmaceutical Manufacturing and Packing Source®



NOVARTIS
Contract
Manufacturing



Simtra
BioPharma Solutions



Molly at ten: a decade of enabling patients' independence

Ten years after its first regulatory approval, SHL Medical's Molly auto-injector has become one of the industry's most established self-injection platforms, supporting millions of patients worldwide. The platform's success reflects not only a decade of market experience but also decades of device engineering expertise that helped shape its development.

The Molly auto-injector emerged from SHL Medical's ambition to create a solution that balanced reliability, simplicity and scalability. Building on lessons learned from the company's pioneering DAI auto-injector, the team combined proven technologies with innovation to develop a robust two-step injection mechanism. The result was a platform designed to simplify the patient experience while meeting the rigorous requirements of pharmaceutical companies developing complex combination products.

From the beginning, close collaboration with pharma partners played an important role in Molly's evolution. Diverse customer requirements challenged SHL Medical to expand the platform's capabilities, resulting in solutions that addressed everything from indication-specific usability needs to manufacturing and operational considerations.

As interest in the platform grew, these partnerships also drove the development of new formats. A notable milestone was the introduction of the Molly 2.25ml format, which enabled the launch of one of the first auto-injector-based therapies with a label volume of 2ml or more, helping pave the way for

a new generation of high-dose biologic treatments administered at home.

As demand increased, SHL Medical invested heavily in transforming Molly into a true global platform. Leveraging the company's vertically integrated approach to toolmaking, equipment development and manufacturing, Molly was engineered for consistency, scalability and efficient adoption across multiple customer programmes. This platform mindset helped reduce complexity while maintaining the high levels of reliability that have become synonymous with the device.

Today, Molly is firmly established as a global market leader. The platform has supported the approval of more than 20 combination products across nearly 30 therapeutic indications, including therapies in dermatology, autoimmune diseases and cardiometabolic care. In 2025 alone, 90 million Molly devices were delivered to patients across the globe, underscoring the platform's significant impact on self-administered drug delivery.

Looking ahead, SHL Medical continues to invest in the future of the platform. Sustainability remains a key focus, with the introduction of a low-footprint version of Molly that reduces associated carbon emissions by up to 60%. At the same time, the company is expanding its global manufacturing and final assembly capabilities to support growing demand while improving supply chain resilience.

A decade after its first approval, Molly's success continues to be defined by a combination of innovation, adaptability and operational excellence. With a foundation built on real-world experience and a commitment to continuous improvement, the platform is well positioned to support the next generation of self-injection therapies and meet the evolving needs of patients and pharma partners worldwide.

